Zealand Pharma A/S Asset Resilience Ratio
Zealand Pharma A/S asset resilience ratio. Zealand Pharma A/S (ZEAL) has an Asset Resilience Ratio of 63.98% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ZEAL total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zealand Pharma A/S (2007–2025)
Asset resilience ratio of Zealand Pharma A/S from 2007 to 2025. This chart shows how Zealand Pharma A/S's Asset Resilience Ratio has changed over time. See ZEAL free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Zealand Pharma A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ZEAL current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr10.53 Billion | 63.98% |
| Total Liquid Assets | Dkr10.53 Billion | 63.98% |
Asset Resilience Insights
- Very High Liquidity: Zealand Pharma A/S maintains exceptional liquid asset reserves at 63.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Zealand Pharma A/S Industry Peers by Asset Resilience Ratio
Compare Zealand Pharma A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
Zealand Pharma A/S Asset Resilience Ratio by Year (2007–2025)
Zealand Pharma A/S asset resilience ratio by year from 2007 to 2025. The table below shows the annual Asset Resilience Ratio data for Zealand Pharma A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 63.98% | Dkr10.53 Billion ≈ $1.65 Billion |
Dkr16.46 Billion ≈ $2.58 Billion |
-17.51pp |
| 2024-12-31 | 81.49% | Dkr7.75 Billion ≈ $1.21 Billion |
Dkr9.51 Billion ≈ $1.49 Billion |
+21.70pp |
| 2023-12-31 | 59.79% | Dkr1.18 Billion ≈ $185.21 Million |
Dkr1.98 Billion ≈ $309.78 Million |
+52.73pp |
| 2022-12-31 | 7.05% | Dkr108.61 Million ≈ $16.99 Million |
Dkr1.54 Billion ≈ $240.91 Million |
-7.41pp |
| 2021-12-31 | 14.46% | Dkr299.04 Million ≈ $46.79 Million |
Dkr2.07 Billion ≈ $323.50 Million |
-0.99pp |
| 2020-12-31 | 15.45% | Dkr297.35 Million ≈ $46.52 Million |
Dkr1.92 Billion ≈ $301.12 Million |
-3.27pp |
| 2019-12-31 | 18.72% | Dkr299.45 Million ≈ $46.85 Million |
Dkr1.60 Billion ≈ $250.26 Million |
-5.56pp |
| 2018-12-31 | 24.28% | Dkr298.61 Million ≈ $46.72 Million |
Dkr1.23 Billion ≈ $192.41 Million |
+14.09pp |
| 2017-12-31 | 10.19% | Dkr75.11 Million ≈ $11.75 Million |
Dkr737.24 Million ≈ $115.35 Million |
+3.16pp |
| 2013-12-31 | 7.03% | Dkr24.38 Million ≈ $3.81 Million |
Dkr346.91 Million ≈ $54.28 Million |
-17.27pp |
| 2012-12-31 | 24.30% | Dkr126.94 Million ≈ $19.86 Million |
Dkr522.40 Million ≈ $81.73 Million |
-7.51pp |
| 2011-12-31 | 31.81% | Dkr149.36 Million ≈ $23.37 Million |
Dkr469.48 Million ≈ $73.45 Million |
+20.05pp |
| 2010-12-31 | 11.76% | Dkr53.00 Million ≈ $8.29 Million |
Dkr450.55 Million ≈ $70.49 Million |
+11.11pp |
| 2009-12-31 | 0.65% | Dkr1.03 Million ≈ $161.78K |
Dkr158.68 Million ≈ $24.83 Million |
-0.41pp |
| 2008-12-31 | 1.06% | Dkr2.40 Million ≈ $375.03K |
Dkr225.24 Million ≈ $35.24 Million |
-0.63pp |
| 2007-12-31 | 1.69% | Dkr4.46 Million ≈ $698.43K |
Dkr263.37 Million ≈ $41.21 Million |
-- |
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treat… Read more